GHRS Reports $280.7M Cash, $48.3M Net Loss, +$38.8M R&D, Phase 2b MADRS -15.5, 57.5% Remission, FDA Alignment Target 2026
GH Research PLC Ordinary Shares · Now $24.83
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS